vs

Side-by-side financial comparison of DaVita (DVA) and Emerson Electric (EMR). Click either name above to swap in a different company.

Emerson Electric is the larger business by last-quarter revenue ($4.6B vs $3.6B, roughly 1.3× DaVita). Emerson Electric runs the higher net margin — 13.5% vs 6.5%, a 7.1% gap on every dollar of revenue. On growth, DaVita posted the faster year-over-year revenue change (12.3% vs 3.0%). Over the past eight quarters, DaVita's revenue compounded faster (6.6% CAGR vs -0.6%).

DaVita Inc. is an American company that provides kidney dialysis services through a network of 2,675 outpatient centers in the United States, serving 200,800 patients, and 367 outpatient centers in 11 other countries serving 49,400 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

DVA vs EMR — Head-to-Head

Bigger by revenue
EMR
EMR
1.3× larger
EMR
$4.6B
$3.6B
DVA
Growing faster (revenue YoY)
DVA
DVA
+9.3% gap
DVA
12.3%
3.0%
EMR
Higher net margin
EMR
EMR
7.1% more per $
EMR
13.5%
6.5%
DVA
Faster 2-yr revenue CAGR
DVA
DVA
Annualised
DVA
6.6%
-0.6%
EMR

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
DVA
DVA
EMR
EMR
Revenue
$3.6B
$4.6B
Net Profit
$234.2M
$618.0M
Gross Margin
53.1%
Operating Margin
15.5%
Net Margin
6.5%
13.5%
Revenue YoY
12.3%
3.0%
Net Profit YoY
43.8%
43.7%
EPS (diluted)
$3.22
$1.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DVA
DVA
EMR
EMR
Q2 26
$4.6B
Q1 26
$3.6B
$4.3B
Q4 25
$3.6B
$4.3B
Q3 25
$3.4B
$4.9B
Q2 25
$3.4B
$4.6B
Q1 25
$3.2B
$4.4B
Q4 24
$3.3B
$4.2B
Q3 24
$3.3B
$4.6B
Net Profit
DVA
DVA
EMR
EMR
Q2 26
$618.0M
Q1 26
$234.2M
$606.0M
Q4 25
$234.2M
$605.0M
Q3 25
$150.3M
$637.0M
Q2 25
$199.3M
$586.0M
Q1 25
$162.9M
$485.0M
Q4 24
$259.3M
$585.0M
Q3 24
$214.7M
$996.0M
Gross Margin
DVA
DVA
EMR
EMR
Q2 26
53.1%
Q1 26
53.2%
Q4 25
53.2%
Q3 25
51.9%
Q2 25
52.6%
Q1 25
53.5%
Q4 24
53.5%
Q3 24
51.3%
Operating Margin
DVA
DVA
EMR
EMR
Q2 26
Q1 26
15.5%
Q4 25
15.5%
17.8%
Q3 25
14.8%
16.4%
Q2 25
15.9%
16.1%
Q1 25
13.6%
14.2%
Q4 24
17.2%
18.6%
Q3 24
16.4%
14.7%
Net Margin
DVA
DVA
EMR
EMR
Q2 26
13.5%
Q1 26
6.5%
13.9%
Q4 25
6.5%
13.9%
Q3 25
4.4%
13.1%
Q2 25
5.9%
12.9%
Q1 25
5.1%
10.9%
Q4 24
7.9%
14.0%
Q3 24
6.6%
21.6%
EPS (diluted)
DVA
DVA
EMR
EMR
Q2 26
$1.10
Q1 26
$3.22
$1.07
Q4 25
$3.22
$1.07
Q3 25
$2.04
$1.12
Q2 25
$2.58
$1.04
Q1 25
$2.00
$0.86
Q4 24
$3.08
$1.02
Q3 24
$2.50
$1.74

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DVA
DVA
EMR
EMR
Cash + ST InvestmentsLiquidity on hand
$700.7M
$1.8B
Total DebtLower is stronger
$10.2B
$13.4B
Stockholders' EquityBook value
$-651.1M
$20.3B
Total Assets
$17.5B
$42.1B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DVA
DVA
EMR
EMR
Q2 26
$1.8B
Q1 26
$700.7M
$1.7B
Q4 25
$700.7M
Q3 25
$736.5M
Q2 25
$739.4M
Q1 25
$511.9M
Q4 24
$846.0M
Q3 24
$1.1B
Total Debt
DVA
DVA
EMR
EMR
Q2 26
$13.4B
Q1 26
$10.2B
$13.4B
Q4 25
$10.2B
$7.6B
Q3 25
$10.2B
$8.9B
Q2 25
$10.1B
$8.3B
Q1 25
$9.6B
$8.2B
Q4 24
$9.2B
$6.6B
Q3 24
$9.3B
$7.7B
Stockholders' Equity
DVA
DVA
EMR
EMR
Q2 26
$20.3B
Q1 26
$-651.1M
$20.3B
Q4 25
$-651.1M
$20.3B
Q3 25
$-571.9M
$20.3B
Q2 25
$-369.6M
$19.9B
Q1 25
$-267.1M
$19.2B
Q4 24
$121.1M
$20.5B
Q3 24
$386.7M
$21.6B
Total Assets
DVA
DVA
EMR
EMR
Q2 26
$42.1B
Q1 26
$17.5B
$41.9B
Q4 25
$17.5B
$41.9B
Q3 25
$17.6B
$42.0B
Q2 25
$17.5B
$42.5B
Q1 25
$17.1B
$42.0B
Q4 24
$17.3B
$42.6B
Q3 24
$17.5B
$44.2B
Debt / Equity
DVA
DVA
EMR
EMR
Q2 26
0.66×
Q1 26
0.66×
Q4 25
0.37×
Q3 25
0.44×
Q2 25
0.42×
Q1 25
0.42×
Q4 24
75.76×
0.32×
Q3 24
23.95×
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DVA
DVA
EMR
EMR
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$694.0M
FCF MarginFCF / Revenue
15.2%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DVA
DVA
EMR
EMR
Q2 26
Q1 26
Q4 25
$540.7M
$699.0M
Q3 25
$841.5M
$3.1B
Q2 25
$324.2M
$1.1B
Q1 25
$180.0M
$241.0M
Q4 24
$547.6M
$777.0M
Q3 24
$810.4M
$3.3B
Free Cash Flow
DVA
DVA
EMR
EMR
Q2 26
$694.0M
Q1 26
$602.0M
Q4 25
$395.3M
$602.0M
Q3 25
$675.4M
$2.7B
Q2 25
$203.1M
$977.0M
Q1 25
$36.8M
$154.0M
Q4 24
$377.0M
$694.0M
Q3 24
$671.4M
$2.9B
FCF Margin
DVA
DVA
EMR
EMR
Q2 26
15.2%
Q1 26
13.9%
Q4 25
10.9%
13.9%
Q3 25
19.7%
54.9%
Q2 25
6.0%
21.5%
Q1 25
1.1%
3.5%
Q4 24
11.4%
16.6%
Q3 24
20.6%
63.1%
Capex Intensity
DVA
DVA
EMR
EMR
Q2 26
4.0%
Q1 26
2.2%
Q4 25
4.0%
2.2%
Q3 25
4.9%
8.9%
Q2 25
3.6%
2.0%
Q1 25
4.4%
2.0%
Q4 24
5.2%
2.0%
Q3 24
4.3%
9.1%
Cash Conversion
DVA
DVA
EMR
EMR
Q2 26
Q1 26
Q4 25
2.31×
1.16×
Q3 25
5.60×
4.86×
Q2 25
1.63×
1.83×
Q1 25
1.10×
0.50×
Q4 24
2.11×
1.33×
Q3 24
3.77×
3.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons